R&D Pipeline

Phase:

Therapy:

Pipeline last updated 30 October 2014
Compound/indication Phase 1 Phase 2 Phase 3 Filed
Liraglutide 3 mg (NN8022)

Obesity
G530L (NN9030)

Obesity
  •